EUCTR2007-000219-27-ES进行中（未招募）不适用
Estudio de fase 3, abierto y aleatorizado, de inotuzumab ozogamicina (CMC-544) administrado en combinación con rituximab, comparado con un tratamiento definido a elección del investigador, a sujetos con linfoma no Hodgkin de células B folicular, CD22 positivo, en recidiva o refractarioAn Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma
Wyeth Research Division of Wyeth Pharmaceuticals Inc0 个研究点目标入组 978 人开始时间: 2008年2月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 978
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects with a diagnosis of CD20/and CD22-positive, follicular grade 1-3a lymphoma, who have received 1 or 2 prior regimens, at least 1 of which should have contained administration of rituximab (either as a single agent or in combination). Diagnoses made within 1 year of randomization do not need to be repeated. Maintenance therapy with rituximab should be considered part of the preceding induction regimen.
- •2. Prior CD20 and /CD22-immunophenotyping of tumors to document B-cell NHL. If such prior documentation is not available, then the immunophenotype of the current disease must be documented by fine-needle aspirate or biopsy, or by circulating CD20 and/CD22-positive NHL cells from peripheral blood before randomization.
- •3. Age 18 years or older.
- •4. Eastern Cooperative Oncology Group (ECOG) performance status = 2.
- •5. Life expectancy = 12 weeks.
- •6. Absolute neutrophil count (ANC) = 1.5 x 109/L (1500/mL) and platelets = 75 x 109/L (75,000/mL).
- •7. Serum creatinine = 1.5 x the upper limit of normal (ULN) and urine protein to creatinine ratio of = 0.2.
- •8. Total bilirubin =1.5 x ULN, AST and alanine aminotransferase (ALT) = 2.5 x ULN.
- •9. At least 1 measurable disease lesion that is = 1.5 cm x 1.5 cm by computed tomography (CT) or magnetic resonance imaging (MRI) at the time of inclusion, in an area of no prior radiation therapy, or documented progression in an area that was previously irradiated.
- •10. Negative serum pregnancy test performed within 1 week before administration of the first dose of test article if the subject is a woman of childbearing potential (if the subject is male, this criterion is considered to be met). A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
- •11. Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control for the duration of the study, including up to 12 months after the last dose of test article. Sexually active males and females using oral contraceptive pills should also use barrier contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with a prior allogeneic hematopoietic stem cell transplant (HSCT).
- •2. Subjects with clinical evidence of transformation to a more aggressive subtype of lymphoma or gradestage 3B follicular lymphoma.
- •3. Subjects with prior autologous transplant within 6 months before administration of the first dose of test article.
- •4. Prior treatment with anti-CD22 antibodies or any previous radio-immuno therapy.
- •5. Subjects whose disease is primary rituximab refractory, meaning that they did not have a CR or PR or that they experienced disease progression within 6 months after their first dose of rituximab or rituximab containing treatment regimen.
- •6. Subjects whose disease is otherwise rituximab refractory, meaning that they did not have a CR or PR or had disease progression within 6 months after their first dose of rituximab within their second course of rituximab or rituximab-containing treatment regimen.
- •7. Major surgery, not related to debulking surgical procedures, within 21 days before screening.
- •8. Chemotherapy, cancer immunosuppressive therapy, radiotherapy, growth factors (except erythropoietin), or investigational agents within 28 days before administration of the first dose of test article. Subjects receiving high doses of corticosteroids must have had their doses tapered to a stable and acceptable level (i.e. physiological replacement dose) at least 28 days before administration of the first dose of test article. On dose days, subjects should not take any corticosteroids apart forfrom the premedication and corticosteroids included in the prescribed chemotherapy regimen described by the protocol, as well as any corticosteroids needed for physiological replacement.
- •9. Prior chemotherapy with nitrosoureas or mitomycin C within 6 weeks before administration of the first dose of test article.
- •10. Subjects who are not eligible for at least 1 of the 2 treatment options in arm 2.
- •11. Cardiac function, as measured by left ventricular ejection fraction (LVEF), is outside of the institutional limits of normal.
- •12. Female subjects who are pregnant or breastfeeding (if the subject is male, this criterion is considered to be not met).
- •13. Central nervous system (CNS) NHL; a lumbar puncture is not required unless CNS involvement with NHL is clinically suspected.
- •14. Subjects with known systemic vasculitides (eg, Wegener's granulomatosis, polyarteritis nodosa, systemic lupus erythematosus).
- •15. Known seropositivity for human immunodeficiency virus (HIV); current or chronic hepatitis B or hepatitis C infection.
- •16. Subjects with a history of veno-occlusive disease or chronic liver disease, such as cirrhosis or chronic hepatitis due to any cause, or are suspected of alcohol abuse.
- •17. Subjects with > grade 1 neuropathy.
- •18. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the investigator’s judgment, increase the risk associated with the subject’s participation in the study.
- •19. Any evidence of serious active infection (ie, requiring an intravenous [IV] antibiotic or antiviral agent).
- •20. Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix.
- •21. Subjects with previous malignancies are eligible provided that they have been disease free for 5 years or more. Subjects with a history of basal cell or squamous cell carc
研究者
相似试验
进行中（未招募）
不适用
?Estudio en fase 3, aleatorizado y abierto, de la eficacia y seguridad de PF-02341066 frente a quimioterapia estándar (pemetrexed o docetaxel) en pacientes con cáncer de pulmón no microcítico (NSCLC) avanzado que presentan una translocación o inversión en el locus del gen de la quinasa de linfoma anaplásico (ALK)?PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSCANCER DE PULMON NO MICROCÍTICO (NSCLC) AVANZADO QUE PRESENTA UNA TRANSLOCACIÓN O INVERSIÓN EN EL LOCUS DEL GEN DE LA QUINASA DE LINFOMA ANAPLÁSICO (ALK)ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSMedDRA version: 12.0Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2009-012595-27-ESPfizer, S.A.318
进行中（未招募）
1 期
?Estudio en Fase 3, aleatorizado y abierto de la eficacia y seguridad de crizotinib frente a pemetrexed /cisplatino o pemetrexed /carboplatino en pacientes no tratados previamente con carcinoma de pulmón no escamoso que entrañe una situación de translocación o inversión con implicación del locus del gen quinasa del linfoma anaplásico (ALK)?PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSCáncer de pulmón no microcítico (CPNM)Non-small cell lung cancer (NSCLC)MedDRA version: 12.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2010-021336-33-ESPfizer, S.A.344
进行中（未招募）
1 期
Estudio de fase III, randomizado, abierto, para comparar la farmacocinética, eficacia y seguridad de trastuzumab por vía subcutánea (SC) con trastuzumab por vía intravenosa (IV) administrado a mujeres con cáncer de mama precoz (CMP) HER2 positivo.Cáncer de mama localmente avanzado, inflamatorio o en estadio inicial HER2 positivoMedDRA version: 9.1Level: LLTClassification code 10006194Term: Breast cancer NOS stage IMedDRA version: 9.1Level: LLTClassification code 10006195Term: Breast cancer NOS stage IIMedDRA version: 9.1Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-007326-19-ESF. Hoffmann-La Roche Ltd552
进行中（未招募）
1 期
Estudio en fase III aleatorizado y abierto para comparar GSK2118436 con DTIC en sujetos con melanoma avanzado (estadio III) o metastásico (estadio IV) y mutación de BRAF, no tratados previamente.A Phase III randomized, open-label study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma.EUCTR2009-015298-11-ESGlaxoSmithKline, S.A.200
进行中（未招募）
不适用
Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âgés de 18 à 65 ans inclus en première ligne. - Manteau 2007 SJ LyMa (Sujets Jeunes)Traitement d'entretien de patients porteur d'un lymphome du manteau en réponse.MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2007-004644-70-BEGOELAMS